NEVNUCLAB at the OECD NEA Workshop on Medical Radioisotopes Supply

NEVNUCLAB • November 20, 2026

NEVNUCLAB took part in the Third International Workshop on Medical Radioisotopes Supply, co-organized by the OECD Nuclear Energy Agency and the U.S. Department of Energy, alongside more than 130 participants from medicine, research, government, and industry.

The workshop took place on April 9 and 10, 2026, at the offices of the OECD Nuclear Energy Agency (NEA) in Boulogne-Billancourt, near Paris. NEVNUCLAB was represented by its CEO and co-founder, Carlo A. Valli.

Group photo of the workshop participants
Workshop participants in front of the OECD NEA offices, April 2026. Photo: © OECD/NEA

Participants included medical doctors, researchers, nuclear medicine specialists, government representatives, and industry professionals. Over two days, they discussed the status of the supply of critical medical radioisotopes, current trends in radioligand therapy (RLT) and theranostics, and the regulatory challenges that come with them.

Sessions examined the clinical results and public health impact of RLT, and the scale-up of production for therapeutic isotopes such as lutetium-177 (Lu-177), actinium-225 (Ac-225), and lead-212 (Pb-212). The workshop also addressed the resilience of the molybdenum-99 (Mo-99) supply chain, a focus of NEA work for more than 15 years. Other topics included healthcare system readiness, regional and national programs for Mo-99 and next-generation therapeutic isotopes, waste management after treatment, radiological protection, and transportation.

Secure supply of next-generation medical isotopes is at the heart of NEVNUCLAB’s work. Speakers emphasized the need for stronger coordination, better data sharing, and more structured collaboration across governments, industry, and international organizations.

“Institutions may have different mandates, but the goal is shared: securing the supply of medical isotopes for patients. That principle is at the core of how we have built NEVNUCLAB,” said Carlo A. Valli, CEO and co-founder of NEVNUCLAB.

NEVNUCLAB follows the NEA’s work on the security of supply of medical radioisotopes and contributes to the international dialogue between producers, research institutions, regulators, and the medical community.

Read the NEA summary of the workshop

Previous article: NEVNUCLAB Announces Two Executive Hires

Share on WhatsApp Share by email